Developmental dependence, the role of the kinases p38 MAPK and PKC, and the involvement of tumor necrosis factor-R1 in the induction of mGlu-5 LTD in the dentate gyrus.
The mechanisms of mGluR-LTD were studied in the dentate gyrus in vitro. The most effective protocol for inducing mGluR-LTD in 6-8 week animals was brief high frequency stimulation (HFS) applied in the presence of the NMDAR antagonist AP5. Evidence for HFS inducing LTD via activation of perisynaptically located mGluRs was established, as an inhibitor of glutamate transporter potentiated HFS-LTD. HFS-LTD was mainly mediated by activation of mGluR5, although a partial involvement of mGluR1 was found. (RS)-3,5-Dihydroxyphenylglycine (DHPG) also induced LTD, but in an age dependent manner, being large in 2 week animals but absent in 6-8 week animals. DHPG-LTD in the dentate gyrus also had a much slower rise time than that in CA1, and unlike CA1, the expression/maintenance of mGluR-LTD was not inhibited by mGluR antagonists. The use of pharmacological inhibitors showed that the induction of HFS-LTD was partially dependent upon activation of L-type Ca channels, release of Ca from ryanodine receptor-sensitive intracellular Ca stores, and the kinases p38 mitogen-activated protein kinase (MAPK), protein kinase C (PKC), but not c-Jun N-terminal kinase or COX-2. Evidence for the involvement of tumor necrosis factor-receptor 1 (TNF-R1) in the induction of mGluR-LTD was presented in the present study, with both HFS-mGluR-LTD and DHPG-LTD being absent in mutant mice null for TNF-R1.
Wang
Q
Q
Department of Physiology, Trinity College, Dublin 2, Ireland.
Chang
L
L
Rowan
M J
MJ
Anwyl
R
R
D000375:Aging / Q000502:physiology; D000818:Animals; D018891:Dentate Gyrus / Q000187:drug effects / Q000254:growth & development* / Q000502:physiology*; D004558:Electric Stimulation; D004594:Electrophysiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D019706:Excitatory Postsynaptic Potentials / Q000235:genetics / Q000502:physiology; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000031:analogs & derivatives / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009473:Neuronal Plasticity / Q000187:drug effects / Q000502:physiology; D018408:Patch-Clamp Techniques; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000502:physiology*; D051381:Rats; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate / Q000502:physiology*; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000235:genetics / Q000502:physiology*; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000502:physiology*
D004791:Enzyme Inhibitors; C578936:Grm5 protein, mouse; C578937:Grm5 protein, rat; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate; D047888:Receptors, Tumor Necrosis Factor, Type I; D008734:Methoxyhydroxyphenylglycol; D011493:Protein Kinase C; D048051:p38 Mitogen-Activated Protein Kinases; C010117:3,4-dihydroxyphenylglycol